• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人星形细胞瘤中 pERK 和 pAKT 的表达:与 IDH1-R132H 存在、血管内皮生长因子、微血管特征和临床结局的相关性。

Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.

机构信息

First Department of Pathology, Laiko Hospital, National and Kapodistrian University of Athens, Medical School, 75 Mikras Asias Street, Athens, Greece.

出版信息

Virchows Arch. 2011 Jun;458(6):749-59. doi: 10.1007/s00428-011-1074-1. Epub 2011 Apr 15.

DOI:10.1007/s00428-011-1074-1
PMID:21494763
Abstract

Although pERK and pAKT are reportedly activated in various neoplasms, little information is available about their significance in astrocytomas. Paraffin-embedded tissue from 82 patients with diffuse infiltrating astrocytomas (grades II to IV) was investigated for the association of pERK and pAKT activation with clinicopathological features, vascular endothelial growth factor (VEGF), isocitrate dehydrogenase 1 and microvascular parameters. Nuclear pERK labelling index (LI) increased with increasing cytoplasmic pERK LI and nuclear and cytoplasmic pAKT LI (p = 0.0019, p = 0.0260 and p = 0.0012, respectively). Accordingly, cytoplasmic pERK increased with increasing levels of nuclear (p = 0.0001) and marginally with cytoplasmic pAKT LI (p = 0.0526). Nuclear and cytoplasmic pERK LI and nuclear pAKT LI were positively correlated with tumour histological grade (p = 0.0040, p = 0.0238 for pERK and p = 0.0004 for pAKT, respectively). VEGF expression was correlated with nuclear pERK (p = 0.0099) and nuclear pAKT LI (p = 0.0002). Interestingly, pERK cytoplasmic LI increased with microvessel calibre (p = 0.0287), whereas pAKT nuclear LI was marginally related to microvessel density (p = 0.0685). The presence of IDH1-R132H was related only to histological grade and lower microvessel calibre. Multivariate survival analysis in the entire cohort selected cytoplasmic pAKT LI (p = 0.045), histological grade, microvessel calibre (p = 0.028), patients' age, gender and surgical excision as independent predictors of survival. Moreover, in glioblastomas, pERK nuclear LI emerged as a favourable prognosticator in the presence of IDH1-R132H. pERK and pAKT in astrocytomas are interrelated and associated with tumour grade and angiogenesis. Moreover, the importance of cytoplasmic pAKT immunoexpression in patients' prognosis and nuclear pERK immunoexpression in glioblastomas is confirmed.

摘要

尽管报道称 pERK 和 pAKT 在各种肿瘤中被激活,但关于它们在星形细胞瘤中的意义的信息却很少。研究了 82 例弥漫浸润性星形细胞瘤(II 级至 IV 级)患者的石蜡包埋组织,以探讨 pERK 和 pAKT 激活与临床病理特征、血管内皮生长因子(VEGF)、异柠檬酸脱氢酶 1 和微血管参数的关系。核 pERK 标记指数(LI)随细胞质 pERK LI 和核及细胞质 pAKT LI 的增加而增加(p=0.0019,p=0.0260,p=0.0012)。因此,细胞质 pERK 随核(p=0.0001)和细胞质 pAKT LI 的增加而增加(p=0.0526)。核和细胞质 pERK LI 与核和细胞质 pAKT LI 与肿瘤组织学分级呈正相关(p=0.0040,p=0.0238 用于 pERK,p=0.0004 用于 pAKT)。VEGF 表达与核 pERK(p=0.0099)和核 pAKT LI(p=0.0002)相关。有趣的是,细胞质 pERK LI 随微血管口径的增加而增加(p=0.0287),而核 pAKT LI 与微血管密度呈边缘相关(p=0.0685)。IDH1-R132H 的存在仅与组织学分级和较低的微血管口径相关。在整个队列中,多变量生存分析选择细胞质 pAKT LI(p=0.045)、组织学分级、微血管口径(p=0.028)、患者年龄、性别和手术切除作为生存的独立预测因子。此外,在胶质母细胞瘤中,IDH1-R132H 存在时,核 pERK LI 成为有利的预后预测因子。星形细胞瘤中的 pERK 和 pAKT 相互关联,并与肿瘤分级和血管生成有关。此外,还证实了细胞质 pAKT 免疫表达在患者预后中的重要性以及核 pERK 免疫表达在胶质母细胞瘤中的重要性。

相似文献

1
Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.人星形细胞瘤中 pERK 和 pAKT 的表达:与 IDH1-R132H 存在、血管内皮生长因子、微血管特征和临床结局的相关性。
Virchows Arch. 2011 Jun;458(6):749-59. doi: 10.1007/s00428-011-1074-1. Epub 2011 Apr 15.
2
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.人类星形细胞瘤中PIK3CA和B-RAF基因突变分析:与ERK和AKT激活的关联
Clin Neuropathol. 2010 Jul-Aug;29(4):239-45. doi: 10.5414/npp29239.
3
Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.磷酸化 4E 结合蛋白 1(p-4E-BP1):人星形细胞瘤的一种新的预后标志物。
Histopathology. 2012 Aug;61(2):293-305. doi: 10.1111/j.1365-2559.2012.04236.x. Epub 2012 Jun 13.
4
Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival.Sox11 在星形细胞瘤中的表达:与巢蛋白/间质-上皮转化因子/c-原癌基因 1(Met)/异柠檬酸脱氢酶 1(IDH1)R132H 表达表型、p-Stat-3 和生存的相关性。
Br J Cancer. 2013 May 28;108(10):2142-52. doi: 10.1038/bjc.2013.176. Epub 2013 Apr 25.
5
Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry.星形细胞瘤中 IL-8-STAT-3 通路的预后意义:与 IL-6、VEGF 和微血管形态计量学的相关性。
Cytokine. 2011 Sep;55(3):387-95. doi: 10.1016/j.cyto.2011.05.012.
6
PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.PI3K/AKT 通路改变与具有临床侵袭性和组织学间变性特征的毛细胞型星形细胞瘤亚群有关。
Acta Neuropathol. 2011 Mar;121(3):407-20. doi: 10.1007/s00401-010-0784-9. Epub 2010 Nov 28.
7
Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival.核因子-κB在人星形细胞瘤中的表达:与pIκBa、血管内皮生长因子、Cox-2、微血管特征及生存的关系
Hum Pathol. 2008 Aug;39(8):1143-52. doi: 10.1016/j.humpath.2008.01.020. Epub 2008 May 20.
8
5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas.5-羟甲基胞嘧啶缺失与世界卫生组织II级弥漫性星形细胞瘤患者的预后不良相关。
Sci Rep. 2016 Feb 11;6:20882. doi: 10.1038/srep20882.
9
Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance.pERK 和 pAKT 在小儿高级别星形细胞瘤中的表达:与 YKL40 的相关性及预后意义。
Neuropathology. 2012 Apr;32(2):133-8. doi: 10.1111/j.1440-1789.2011.01252.x. Epub 2011 Oct 6.
10
pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.循环肿瘤细胞中的磷酸化细胞外信号调节激酶/磷酸化蛋白激酶B表型分析作为晚期肝细胞癌患者索拉非尼疗效的生物标志物
Oncotarget. 2016 Jan 19;7(3):2646-59. doi: 10.18632/oncotarget.6104.

引用本文的文献

1
Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments.针对脑癌中的神经炎症:揭示机制、药理学靶点及神经药物研发
Front Pharmacol. 2021 May 18;12:680021. doi: 10.3389/fphar.2021.680021. eCollection 2021.
2
Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1.肿瘤突变负荷可预测异柠檬酸脱氢酶1(IDH1)突变型低级别胶质瘤患者的生存情况。
Neurooncol Adv. 2020 Mar 27;2(1):vdaa042. doi: 10.1093/noajnl/vdaa042. eCollection 2020 Jan-Dec.
3
Overexpression of vascular endothelial growth factor indicates poor outcomes of glioma: a systematic review and meta-analysis.

本文引用的文献

1
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.在人类脑胶质瘤中检测 IDH1 突变:免疫组织化学与测序的比较。
Brain Tumor Pathol. 2011 Apr;28(2):115-23. doi: 10.1007/s10014-011-0023-7. Epub 2011 Feb 23.
2
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.IDH1 野生型间变性星形细胞瘤患者的预后比 IDH1 突变型胶质母细胞瘤差,IDH1 突变状态解释了高龄的不良预后影响:对胶质瘤分类的影响。
Acta Neuropathol. 2010 Dec;120(6):707-18. doi: 10.1007/s00401-010-0781-z. Epub 2010 Nov 19.
3
血管内皮生长因子的过表达提示胶质瘤预后不良:一项系统评价与Meta分析
Int J Clin Exp Med. 2015 Jun 15;8(6):8709-19. eCollection 2015.
4
Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification?弥漫性低级别胶质瘤中恶性进展的微小病灶:胶质瘤分类中创建一个中级别的方向?
Virchows Arch. 2015 Apr;466(4):433-44. doi: 10.1007/s00428-014-1712-5. Epub 2015 Jan 21.
5
Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.PI3K/AKT/mTOR信号通路各组分之间以及与MAPK、JAK/STAT和Notch-1信号通路各组分之间的复杂相互作用,表明它们参与了脑膜瘤的发生发展。
Virchows Arch. 2014 Oct;465(4):473-85. doi: 10.1007/s00428-014-1641-3. Epub 2014 Aug 22.
6
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.硼替佐米以时间依赖性方式克服胶质母细胞瘤细胞系对替莫唑胺的 MGMT 相关耐药性。
Invest New Drugs. 2013 Oct;31(5):1169-81. doi: 10.1007/s10637-013-9968-1. Epub 2013 May 5.
7
Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.IDH 突变在成人低级别胶质瘤中的预后意义:一项荟萃分析。
J Neurooncol. 2013 Jun;113(2):277-84. doi: 10.1007/s11060-013-1107-5. Epub 2013 Mar 16.
8
The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.激活的AKT-mTOR信号通路在人类星形细胞瘤中的临床及预后意义
Neurol Res Int. 2012;2012:454957. doi: 10.1155/2012/454957. Epub 2012 Feb 21.
Targeting a common collaborator in cancer development.
靶向癌症发展中的共同协作因子。
Sci Transl Med. 2010 Sep 8;2(48):48ps45. doi: 10.1126/scitranslmed.3001251.
4
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.功能蛋白质组学剖析癌症中的酪氨酸激酶信号通路。
Nat Rev Cancer. 2010 Sep;10(9):618-29. doi: 10.1038/nrc2900. Epub 2010 Aug 19.
5
Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.西罗莫司抑制 mTOR 并不能减轻 PCK 大鼠肝肾功能的进展。
Nephrol Dial Transplant. 2011 Jan;26(1):92-100. doi: 10.1093/ndt/gfq384. Epub 2010 Jul 7.
6
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.人类星形细胞瘤中PIK3CA和B-RAF基因突变分析:与ERK和AKT激活的关联
Clin Neuropathol. 2010 Jul-Aug;29(4):239-45. doi: 10.5414/npp29239.
7
The Ras-ERK pathway: understanding site-specific signaling provides hope of new anti-tumor therapies.Ras-ERK 通路:深入了解特定部位的信号传递为抗肿瘤新疗法带来希望。
Bioessays. 2010 May;32(5):412-21. doi: 10.1002/bies.200900155.
8
Higher pAkt expression predicts a significant worse prognosis in glioblastomas.pAkt 表达水平越高,胶质母细胞瘤的预后越差。
J Radiat Res. 2010;51(3):343-8. doi: 10.1269/jrr.09109. Epub 2010 Apr 12.
9
The PKB/AKT pathway in cancer.癌症中的 PKB/AKT 通路。
Curr Pharm Des. 2010 Jan;16(1):34-44. doi: 10.2174/138161210789941865.
10
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.脑肿瘤中 R132H 突变特异性 IDH1 抗体结合的特征。
Brain Pathol. 2010 Jan;20(1):245-54. doi: 10.1111/j.1750-3639.2009.00352.x. Epub 2009 Oct 27.